Sophiris Bio Inc. (SPHS) Sets New 12-Month High at $5.61
Sophiris Bio Inc. (NASDAQ:SPHS)’s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $5.61 and last traded at $5.27, with a volume of 5,052,377 shares traded. The stock had previously closed at $4.38.
SPHS has been the topic of a number of recent analyst reports. Maxim Group restated a “buy” rating and set a $4.00 target price on shares of Sophiris Bio in a report on Friday, June 10th. Echelon Wealth Partners reiterated a “buy” rating and set a $5.00 price objective on shares of Sophiris Bio in a report on Friday, June 10th.
The firm’s market cap is $110.12 million. The firm’s 50-day moving average is $2.25 and its 200-day moving average is $1.71.
Sophiris Bio (NASDAQ:SPHS) last posted its quarterly earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06. On average, equities analysts forecast that Sophiris Bio Inc. will post ($0.73) earnings per share for the current fiscal year.
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.